The IPO was underwritten by JP Morgan and Morgan Stanley, two of the most active biotech IPO banks, signaling institutional confidence in AgomAb's fibrosis antibody pipeline.
AgomAb was spun out of argenx, Ghent's globally recognized antibody platform company. The Nasdaq listing follows the path of argenx itself and reflects a broader pattern of Belgian biotech companies accessing US public markets for growth capital.